CANDEL THERAPEUTICS INC (CADL) Stock Price, Quote, News and Overview
NASDAQ:CADL - Nasdaq - US1374041093 - Common Stock - Currency: USD
CADL Quote, Performance and Key Statistics
CANDEL THERAPEUTICS INC
NASDAQ:CADL (1/24/2025, 6:19:57 PM)
After market: 6.92 +0.03 (+0.44%)6.89
-0.17 (-2.41%)
The current stock price of CADL is 6.89 USD. In the past month the price decreased by -20.16%. In the past year, price increased by 471.78%.
CADL Latest News, Press Releases and Analysis
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell...
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused...
CADL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.84 | 300.94B | ||
| AMGN | AMGEN INC | 14.33 | 148.05B | ||
| GILD | GILEAD SCIENCES INC | 21.01 | 115.99B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 862 | 113.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.88 | 74.26B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.80B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.47B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.64B | ||
| NTRA | NATERA INC | N/A | 22.13B | ||
| BIIB | BIOGEN INC | 8.95 | 21.30B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.52B |
Related stock screener links
About CADL
Company Profile
Candel Therapeutics, Inc. is a late clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. The company is headquartered in Needham, Massachusetts and currently employs 42 full-time employees. The company went IPO on 2021-07-27. The firm is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The firm has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Company Info
CANDEL THERAPEUTICS INC
117 Kendrick Street,, Suite 450
Needham MASSACHUSETTS US
CEO: Paul Peter Tak
Employees: 42
Company Website: https://www.candeltx.com/
Investor Relations: https://ir.candeltx.com/
Phone: 16179165445
CADL FAQ
What is the stock price of CADL?
The current stock price of CADL is 6.89 USD.
What is the symbol for CANDEL THERAPEUTICS INC stock?
The exchange symbol of CANDEL THERAPEUTICS INC is CADL and it is listed on the Nasdaq exchange.
On which exchange is CADL stock listed?
CADL stock is listed on the Nasdaq exchange.
Is CADL a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for CADL, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of CADL.
Does CADL stock pay dividends?
CADL does not pay a dividend.
What is the Price/Earnings (PE) ratio of CADL?
CADL does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.36).
What is the Short Interest ratio of CADL stock?
The outstanding short interest for CADL is 9.25% of its float.
CADL Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CADL. When comparing the yearly performance of all stocks, CADL is one of the better performing stocks in the market, outperforming 98.9% of all stocks.
CADL Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CADL. CADL may be in some trouble as it scores bad on both profitability and health.
CADL Financial Highlights
Over the last trailing twelve months CADL reported a non-GAAP Earnings per Share(EPS) of -1.36. The EPS decreased by -21.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -92.1% | ||
| ROE | -297.72% | ||
| Debt/Equity | 0.97 |
CADL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CADL. The Buy consensus is the average rating of analysts ratings from 7 analysts.